老年NSCLC晚期患者GP方案化疗3周前后血糖变化及其意义  

Change of Blood Glucose and its Significance in Gemcitabine Plus Cisplatin Chemotherapy on Advanced Non-Small-Cell Lung Cancer in Elderly Patients

作　　者：甘志华[1] 韩坤[1] 林叔陈[1] 姚阳[1] 闵大六[1] 

机构地区：[1]上海交通大学附属第六人民医院东院肿瘤科,上海201306

出　　处：《标记免疫分析与临床》2016年第9期989-991,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：目的 探讨老年NSCLC晚期患者GP方案化疗3周前后血糖变化及其意义.方法 将2012年9月至2015年9月在上海交通大学附属第六人民医院收治的69例NSCLC晚期患者,测定其空腹血糖值,后给予GP方案进行化疗,在化疗进行3周后测定空腹血糖值,对比其化疗前后血糖变化.结果 经过3周化疗,化疗结束后血糖水平在6.1 ～ 7.0mmol/L范围内（IFG）患者13例,占总患者数的18.84％（13/69）,血糖水平大于7.0mmol/L（糖尿病）患者7例,占总患者数的10.14％ （7/69）,其余患者血糖均有不同程度的上升;化疗前69例患者平均血糖水平为4.86±0.82mmol/L,化疗后上升至6.81±1.09mmol/L,化疗后患者血糖水平均有不同程度上升.结论 老年NSCLC晚期患者GP方案化疗3周后血糖均有不同程度的升高,提示在化疗过程中应密切关注血糖变化.Objective To observe the changes of blood glucose and its significance in gemcitabine plus cisplatin chemotherapy （GP） in advanced non-small-cell lung cancer （NSCLC） of elderly three weeks before and after treatment. Methods We enrolled 69 elderly patients who were diagnosed with advanced NSCLC. Fasting blood glucose was assessed before GP and three week after chemotherapy. Results There were 13 cases whose blood glucose levels were within the range of 6.1 - 7.0mmol/L （ impaired fasting glucose）, accounted for 18.84% of the total number of patients （13/69）. Seven cases had blood sugar levels greater than 7.0mmol/L （diabetes mellitus） patients, accounted for the total number of patients of 10.14% （7/12） and the rest of the patients had variable increased blood sugar. The average blood glucose level in all 69 patient before GP chemotherapy was 4.86± 0.82mmol/L and it was 6. 81 ±1.09mmol/L after chemotherapy. Conclusion The increased level of blood sugar after GP chemotherapy in elderly patients with advanced NSCLC suggests that a close attention should be paid to the change of blood glucose during chemotherapy.

关 键 词：老年NSCLC GP方案化疗 3周前后 血糖 

分 类 号：R734.2[医药卫生—肿瘤]